Trial Outcomes & Findings for Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) (NCT NCT00290407)
NCT ID: NCT00290407
Last Updated: 2018-05-04
Results Overview
Study terminated, results data not available
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
2 participants
Primary outcome timeframe
3 months after starting treatment, 6 months after starting treatment, and every 6 months (after completing treatment) until disease progression
Results posted on
2018-05-04
Participant Flow
Participant milestones
| Measure |
RITUXIMAB PLUS ORAL Β-GLUCAN
|
|---|---|
|
Overall Study
STARTED
|
2
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
2
|
Reasons for withdrawal
| Measure |
RITUXIMAB PLUS ORAL Β-GLUCAN
|
|---|---|
|
Overall Study
Physician Decision
|
2
|
Baseline Characteristics
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Baseline characteristics by cohort
| Measure |
RITUXIMAB PLUS ORAL Β-GLUCAN
n=2 Participants
|
|---|---|
|
Age, Customized
Over 18 years of age
|
2 participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 3 months after starting treatment, 6 months after starting treatment, and every 6 months (after completing treatment) until disease progressionStudy terminated, results data not available
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: at weeks 4, 8, 12, and at month 6Outcome measures
Outcome data not reported
Adverse Events
RITUXIMAB PLUS ORAL Β-GLUCAN
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place